Chester County News and Community Website
WILMINGTON, DE — Prelude Therapeutics Incorporated (Nasdaq: PRLD), a precision oncology company, has shared its third-quarter 2024 financial results alongside significant updates on its clinical pipeline. The company continues to …
Prelude Therapeutics Reports Q3 2024 Results and Clinical Progress Read More WILMINGTON, DE — Prelude Therapeutics Incorporated (Nasdaq: PRLD) has unveiled encouraging results from its ongoing Phase 1 trial of PRT3789, a groundbreaking SMARCA2 degrader, at the 36th Annual EORTC-NCI-AACR Symposium …
Prelude Therapeutics Shares Promising Phase 1 Trial Data for PRT3789 at International Symposium Read More WILMINGTON, DE — Prelude Therapeutics Incorporated (Nasdaq: PRLD) has announced the presentation of three significant abstracts at the EORTC-NCI-AACR Symposium in Barcelona. These presentations, held from October 23-25, 2024, highlight their …
Prelude Therapeutics Showcases Innovative SMARCA Degrader Programs at Barcelona Symposium Read More WILMINGTON, DE — Prelude Therapeutics Incorporated this week unveiled interim results from its Phase 1 trial of PRT3789, a pioneering therapy designed to target cancers with a SMARCA4 mutation. The data, …
Prelude Therapeutics Releases Promising Phase 1 Data on Novel Cancer Treatment Read More WILMINGTON, DE — Prelude Therapeutics Incorporated (Nasdaq: PRLD) has revealed groundbreaking clinical data on its novel therapeutic agent, PRT3789, at the European Society of Medical Oncology (ESMO) Congress 2024 in Barcelona. …
Prelude Therapeutics Unveils Promising Data on PRT3789 at ESMO Congress 2024 Read More WILMINGTON, DE — Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, reported its financial results for the second quarter ending June 30, 2024. The company also provided significant …
Prelude Therapeutics Reports Q2 Financial Results and Key Clinical Developments Read More WILMINGTON, DE — Prelude Therapeutics Incorporated (Nasdaq: PRLD) has announced a collaboration with Merck to evaluate a new cancer treatment. The Phase 2 clinical trial will test Prelude’s investigational drug, …
Prelude Therapeutics Joins Forces with Merck for Cancer Treatment Trial Read More WILMINGTON, DE — Prelude Therapeutics Incorporated (Nasdaq: PRLD) announced its participation in two significant healthcare conferences in June. CEO Kris Vaddi, Ph.D., will represent the company at these key industry …
Prelude Therapeutics to Participate in Major Healthcare Conferences Read More WILMINGTON, DE — Prelude Therapeutics Incorporated (Nasdaq: PRLD) will take the stage at the upcoming Citizens JMP Life Sciences Conference in New York City on May 13 and 14.
Prelude Therapeutics to Showcase at Citizens JMP Life Sciences Conference Read More WILMINGTON, DE — Prelude Therapeutics Incorporated (Nasdaq: PRLD) recently shared its first quarter financial results. But even more newsworthy is the ongoing progress and future milestones slated for its novel …
Prelude Therapeutics Progresses in Cutting-Edge Cancer Treatment Development Read More